RT Journal Article
T1 Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.
A1 Sjoquist, Katrin M
A1 Renfro, Lindsay A
A1 Simes, R John
A1 Tebbutt, Niall C
A1 Clarke, Stephen
A1 Seymour, Matthew T
A1 Adams, Richard
A1 Maughan, Timothy S
A1 Saltz, Leonard
A1 Goldberg, Richard M
A1 Schmoll, Hans-Joachim
A1 Van Cutsem, Eric
A1 Douillard, Jean-Yves
A1 Hoff, Paulo M
A1 Hecht, Joel Randolph
A1 Tournigand, Christophe
A1 Punt, Cornelis J A
A1 Koopman, Miriam
A1 Hurwitz, Herbert
A1 Heinemann, Volker
A1 Falcone, Alfredo
A1 Porschen, Rainer
A1 Fuchs, Charles
A1 Diaz-Rubio, Eduardo
A1 Aranda, Enrique
A1 Bokemeyer, Carsten
A1 Souglakos, Ioannis
A1 Kabbinavar, Fairooz F
A1 Chibaudel, Benoist
A1 Meyers, Jeffrey P
A1 Sargent, Daniel J
A1 de Gramont, Aimery
A1 Zalcberg, John R
A1 Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD), 
AB Estimating prognosis on the basis of clinicopathologic factors can inform clinical practice and improve risk stratification for clinical trials. We constructed prognostic nomograms for one-year overall survival and six-month progression-free survival in metastatic colorectal carcinoma by using the ARCAD database. Data from 22 674 patients in 26 randomized phase III clinical trials since 1997 were used to construct and validate Cox models, stratified by treatment arm within each study. Candidate variables included baseline age, sex, body mass index, performance status, colon vs rectal cancer, prior chemotherapy, number and location of metastatic sites, tumor mutation status (BRAF, KRAS), bilirubin, albumin, white blood cell count, hemoglobin, platelets, absolute neutrophil count, and derived neutrophil-to-lymphocyte ratio. Missing data ( In final models, all included variables were associated with overall survival except for lung metastases, and all but total white cell count associated with progression-free survival. No clinically relevant pairwise interactions were identified. Final nomogram calibration was good (C = 0.68 for overall and C = 0.62 for progression-free survival), as was external validity (concordance between predicted >50% vs 50% vs 50% vs  The nomograms are well calibrated and internally and externally valid. They have the potential to aid prognostication and patient-physician communication and balance risk in colorectal cancer trials.
YR 2018
FD 2018
LK https://hdl.handle.net/10668/24662
UL https://hdl.handle.net/10668/24662
LA en
DS RISalud
RD Apr 17, 2025